SCHEMBL19746823

SCHEMBL19746823

Fc1ccc2nc(CCl)oc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PIK3CD O00329 1/20 0.43
PIK3CB P42338 1/20 0.43
GABRP O00591 4/20 0.40
GABRD O14764 4/20 0.40
GABRA1 P14867 4/20 0.40
GABRB1 P18505 4/20 0.40
GABRG2 P18507 4/20 0.40
GABRB3 P28472 4/20 0.40
GABRA5 P31644 4/20 0.40
GABRA3 P34903 4/20 0.40
GABRA2 P47869 4/20 0.40
GABRB2 P47870 4/20 0.40
GABRA4 P48169 4/20 0.40
GABRE P78334 4/20 0.40
GABRA6 Q16445 4/20 0.40
GABRG1 Q8N1C3 4/20 0.40
GABRG3 Q99928 4/20 0.40
GABRQ Q9UN88 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22042970 0.86 PIK3CD (0.43) MAPTKDM4EPIK3CDPIK3CBGABRP
SCHEMBL5794092 0.82 MAPT (0.46) MAPTKDM4EPIK3CDPIK3CBGABRP
SCHEMBL16067280 0.82 MAPT (0.50) MAPTKDM4EPIK3CDPIK3CBGABRP
SCHEMBL6869457 0.81 MAPT (0.46) MAPTKDM4EPIK3CDPIK3CBGABRP
SCHEMBL486127 0.80 PIK3CG (0.58) MAPTKDM4ENPC1RAB9ASOS1
SCHEMBL30358396 0.79 MAPT (0.44) MAPTKDM4EPIK3CDPIK3CBGABRP
SCHEMBL23932508 0.79 MAPT (0.46) MAPTKDM4EDAGLANPC1RAB9A
SCHEMBL4288555 0.79 KDM4E (0.74) MAPTKDM4EPIK3CDPIK3CBNPC1
SCHEMBL30041004 0.79 MAPT (0.46) MAPTKDM4EDAGLANPC1RAB9A
SCHEMBL9199893 0.79 ESR1 (0.53) MAPTKDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163073-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2025-05-22 US disclosed
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 CN disclosed
CN-119775223-A Benzoxazole derivative containing dithioacetal unit, and preparation method and application thereof 贵州大学 2025-04-08 CN disclosed
CN-115427404-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-12-13 CN disclosed
US-12077547-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-09-03 US disclosed
CN-115160339-B Aldose reductase inhibitors and methods of use thereof 纽约市哥伦比亚大学理事会 2024-05-14 CN disclosed
EP-4316603-A2 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2024-02-07 EP disclosed
EP-3757107-B1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2023-10-25 EP disclosed
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-10-05 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-3757107-A1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2020-12-30 EP disclosed
US-10870658-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-12-22 US disclosed
US-20200283451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-09-10 US disclosed
EP-3352754-B1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2020-09-02 EP disclosed
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-12 US disclosed
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-10-03 US disclosed
US-10150779-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-12-11 US disclosed
US-20180237451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2018-08-23 US disclosed
EP-3352754-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2018-08-01 EP disclosed
WO-2017223179-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163073-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-10870658-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 MAPT 3388/4885KDM4E 1980/4885PIK3CD 3553/4885
US-20200283451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-20180237451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-10150779-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885
US-12077547-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 MAPT 1189/4885KDM4E 2144/4885PIK3CD 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.